Hepatitis C genotype 1b and 4 cured after telaprevir-based therapy

Autor: Diego Pérez-Parente, Sandra Suárez-Ordóñez, Marta Suárez-Santamaría, Luis E. Morano-Amado

Publikováno v: Revista Espanola de Enfermedades Digestivas, Vol 107, Iss 4, Pp 251-251 (2015)

Externí odkaz: https://doaj.org/article/e0870c8449b54300af211ae99b219fcd

Similar recovery of liver function after response to all‐oral HCV therapy in patients with cirrhosis with and without HIV coinfection

Autor: Juan, Macías, Rafael, Granados, Francisco, Téllez, Dolores, Merino, Montserrat, Pérez, Luis E, Morano, Rosario, Palacios, María, Paniagua, Mario, Frías, Nicolás, Merchante, Juan A, Pineda, Carla, Toyas

Publikováno v: Digital.CSIC. Repositorio Institucional del CSIC
instname

Among patients with cirrhosis, recovery of liver function after SVR to all‐oral direct‐acting antivirals (DAA ) in HIV /HCV coinfection could be different to that in HCV monoinfection. Because of this, we compared the changes in several markers o

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::467b06a3e0c39a900f4bc2fa1f30e615
http://hdl.handle.net/10261/213405

HIV-coinfected patients respond worse to direct-acting antiviral-based therapy against chronic hepatitis C in real life than HCV-monoinfected individuals: a prospective cohort study

Autor: Marta Montero-Alonso, Maria Rios, Sergio Reus-Bañuls, Luis E. Morano-Amado, Paloma Geijo-Martínez, Francisco Téllez, Karin Neukam, Antonio Collado, Francisco Jesús Vera-Méndez, Ignacio de los Santos-Gil, Marta Suárez-Santamaría, Juan A. Pineda, María Mancebo, Antonio Rivero-Juárez, Rafael Granados

Publikováno v: HIV CLINICAL TRIALS
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname

Objective: HIV/HCV-coinfected patients and hepatitis C virus (HCV) monoinfected subjects are thought to respond equally to direct-acting antiviral (DAA)-based therapy despite the lack of data derived from clinical trials. This study is aimed to evalu

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8be212ce19441a193dc5205c9af0e9be
https://pubmed.ncbi.nlm.nih.gov/28599618

Efficacy of therapy against chronic hepatitis C virus genotype 1 infection in HIV-coinfected patients with several interferon-free DAA combinations: real life data from the HEPAVIR-DAA Cohort

Autor: M.J. Ríos, Francisco Téllez, Karin Neukam, Luis E. Morano-Amado, E. Nuño-Álvarez, Antonio Rivero-Juárez, Juan Macías, Montserrat Pérez-Pérez, Dolores Merino, Juan A. Pineda

Publikováno v: Journal of Hepatology. 66:S526-S527

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::47e07ad7da9cfa4e4646e84076d2cb64
https://doi.org/10.1016/s0168-8278(17)31454-x

Randomized prospective study evaluating tenofovir disoproxil fumarate prophylaxis against hepatitis B virus reactivation in anti-HBc-positive patients with rituximab-based regimens to treat hematologic malignancies: The Preblin study.

Autor: María Buti, María L Manzano, Rosa M Morillas, Montserrat García-Retortillo, Leticia Martín, Martín Prieto, María L Gutiérrez, Emilio Suárez, Mariano Gómez Rubio, Javier López, Pilar Castillo, Manuel Rodríguez, José M Zozaya, Miguel A Simón, Luis E Morano, José L Calleja, María Yébenes, Rafael Esteban

Publikováno v: PLoS ONE, Vol 12, Iss 9, p e0184550 (2017)

Hepatitis B virus (HBV) reactivation in patients with resolved HBV infection (HBsAg negative, antiHBc positive) is uncommon, but potentially fatal. The role of HBV prophylaxis in this setting is uncertain. The aim of this study was to compare the eff

Externí odkaz: https://doaj.org/article/68eef264915a401c8f160ffb2eb7a295